A recent study reveals a concerning prevalence of substandard cancer drugs in several African nations, including Ethiopia, Kenya, Malawi, and Cameroon. Approximately 17% of tested medications had incorrect active ingredient levels, potentially hindering treatment effectiveness and leading to disease progression. Experts emphasize the urgent need for improved regulation, screening technologies, and enhanced supply chain monitoring to combat this critical issue.